A 76 year old woman presented with locally advanced papillary transitional cell carcinoma. The patient had elsewhere had trans-urethral resection and radiotherapy and declined salvage cystectomy. She was treated with Lonidamine (150 mg × 3/day p.o. Repeat CT scan after 8 months showed partial remission. This response was unchanged after 28 months Lonidamine therapy.
Get full access to this article
View all access options for this article.
References
1.
BandP.R., MarounJ., PritchardK., StewartD., CoppinC.M., WilsonK., EisenhauerE.A.: Phase II study of Lonidaminein patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group Study.Cancer Treat. Rep., 70: 1305, 1986.
2.
BonoA.V., PozziE., BernacchiP., FavaC., RealiL., CiottoliG.B.: Trattamento del carcinoma prostatico con Lonidamina: studio di fase II.Atti del Congresso Screening in Oncologia, 236, Firenze, 13-16 ottobre 1987.
3.
CorsiG., PalazzoG., GermaniC., Scorza BarcellonaP., SilvestriniB.: 1-Halobenzyl-1H-indazole-3-carboxylic acids. A new class of antispermatogenic agents.J. Med. Chem., 19: 778, 1976.
4.
KokronO., MacaS., ScheinerW., De GregorioM., CiottoliG.B.: Lonidamine in non small cell lung cancer. Phase II study.Proceedings of the 14th International Cancer Congress, 4853, 1263. Budapest, August 21-27, 1986.
5.
MagnoL., TerraneoF., ScandolaroR., BertoniF., CiottoliG.B.: Lonidamine and radiotherapy in head and neck cancer.Preliminary report. Proc. ASCO, 6: 126, 1987.
6.
PriviteraG., CiottoliG.B., PataneC., PamucciT., TafuriG., MariettaF., De LucaB., MagnaniF., De GregorioM., GrecoS.: Phase II double-blind randomized study of Lonidamine and radiotherapy in epidermoid carcinoma of the lung.Radiother. Oncol., 10: 285, 1987.
7.
PronzatoP., AmorosoD., BertelliG., ConteP.F., CusimanoM.P., CiottoliG.B., GulisanoM., LionettoR., RossoR.: Phase II study of Lonidamine in metastatic breast cancer.Br. J. Cancer, 59: 251-253, 1989.
8.
WisselO., MagillG., WeltS., O'HehirM., SordilloP., CurrieV.: Phase II trial of Lonidamine (1,-2,4-dichlorophenil-1H-indazol-3-carbozylic acid (LON) in advanced soft tissue sarcomas.Proc. ASCO, 3: 258, 1984.
